At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at jnj.com.

As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit.

Job Function:

Job Sub Function:

Job Category:

All Job Posting Locations:

Job Description:

About Innovative Medicine 

Our expertise in Innovative Medicine is informed and inspired by patients, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow.

Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way.

Learn more at https://www.jnj.com/innovative-medicine

Johnson & Johnson Innovative Medicine is searching for a Access Engagement & HTA Head to join our Market Access Team in Riyadh, Saudi Arabia.

Role Purpose

Reporting to the Market Access Director, this role support J&J Innovative Medicine Saudi Arabia’s access engagement and HTA strategy, positioning the portfolio for success within an evolving Saudi healthcare system.

As a customer- and stakeholder-facing Market Access leader, the role connects policy, HTA and emerging healthcare models with field access execution.

Working closely with HEMAR Leads, SAM, Pricing & Tender, Medical, Commercial and Regulatory teams, the role translates external developments into actionable portfolio and account strategies.

The role is accountable for three strategic priorities:

• Shape the environment through HTA, policy and value dialogue.
• Build for the emerging healthcare model by engaging new entities and developing innovative access solutions.
• Move access closer to customers through differentiated, insight-driven field engagement.
  

Key Responsibilities

• Shape policy and HTA dialogue with MoH, CNHI/CHTA and CHI, anticipating evolving evidence, economic and value requirements and translating them into portfolio, brand and evidence plans.
• Lead the KSA portfolio HTA and Economic Evaluation Study strategy, including Saudi-adapted economic models, local epidemiology, real-world evidence and appropriate comparators, in close partnership with HEMAR and Medical Affairs.
• Monitor major healthcare-system developments, including Vision 2030 healthcare transformation, financing reform and privatization, and translate them into clear access implications, risks and opportunities for the leadership team.
• Activate relevant priorities across HTA and EES activities, strengthening strategic contracting, price protection, value and pricing policy, portfolio value narratives and stakeholder prioritization.
• Represent J&J Innovative Medicine credibly in appropriate policy forums, industry associations and public-private initiatives.

• Establish and deepen strategic relationships with emerging healthcare stakeholders, including CNHI, HHC and healthcare clusters, provider economic functions, and purchasing/contracting organizations.
• Serve as a key Market Access interface with transforming the healthcare ecosystem, identifying changes early and translating them into actionable access opportunities.
• Support developing the innovative access solutions including value-based agreements, outcomes-based contracting, innovative financing, early-access and managed-entry approaches, aligned with evolving purchasing and reimbursement models.
• Develop high-level health-transformation plans reflecting HHC and cluster priorities and connect these plans with portfolio priorities and launch sequencing.
• Apply an integrated planning discipline to strategic access initiatives, with quantified ambition, clear DRI ownership, defined milestones and regular continue/refine/scale/stop decisions.
• Partner with Medical, Commercial, Regulatory, HEMAR and other Access team members to align portfolio strategies with emerging pathways and strengthen organizational readiness for the new healthcare model.

• Build a differentiated customer-facing access engagement model, segmenting stakeholders according to influence, strategic importance and access impact.
• Expand Market Access engagement beyond traditional purchasing stakeholders to include cluster leadership, finance, contracting, HTA committees, insurers and other emerging access decisionmakers.
• Establish a disciplined after-action review approach to evaluate stakeholder reach, conversion, follow-through and value-message effectiveness, translating insights into future engagement priorities.
• Connect national access achievements with account-level execution, ensuring formulary and tender wins translate into sustainable patient access and uptake.

Key Accountabilities / Measures of Success

Success should be measured across impact, execution and customer engagement, rather than activity volume alone:

HTA & Environment Shaping

• HTA/EES portfolio plan delivered against agreed milestones.
• External evidence requirements systematically incorporated into evidence and brand planning.
• Quality and timeliness of HTA/value submissions and strategic narratives.
• Progress against prioritized policy and HTA-shaping initiatives.
  

Health Transformation

• Strategic engagement plans established for priority emerging entities and healthcare clusters.
• Identified transformation opportunities converted into executable access initiatives.
• Innovative contracting/access concepts progressed through defined stage gates.
• Account transformation plans integrated with priority brands and launches.
  

Access Engagement

• Coverage of prioritized access stakeholders.
• Quality and effectiveness of strategic customer interactions.
• Follow-through and conversion of engagement into defined access outcomes.
• Identification and closure of post-formulary/tender implementation gaps.
• Evidence of formulary/tender access translating into patient uptake where measurable.

Qualifications & Experience

• Bachelor’s degree in pharmacy, life sciences, medicine, health economics or a related field; an advanced degree (MSc, MBA, MPH, PharmD or health economics) is preferred.
• 6-10+ years in pharmaceutical or healthcare roles with a strong track record in market access, HEMAR, health policy or health-system transformation; KSA experience is essential.
• Deep working knowledge of the Saudi health system and Vision 2030  - CNHI, HHC and clusters, MoH, SFDA, CHI — and of HTA / EES, formulary and NUPCO tender pathways.
• Demonstrated ability to build senior external relationships and deliver access outcomes across specialty therapy areas.
• Fluency in Arabic and English

Required Skills:

Preferred Skills: